FDA Panel Backs 6 Experimental Peptides for Compounding as Scientists Warn of Liver Damage
Updated
Updated · The Washington Post · Oct 13
FDA Panel Backs 6 Experimental Peptides for Compounding as Scientists Warn of Liver Damage
3 articles · Updated · The Washington Post · Oct 13
Summary
A July FDA advisory panel voted to ease restrictions on six unapproved peptides — including BPC-157, TB-500 and MOTS-c — by recommending they be added to the 503A bulks list for compounding pharmacies.
The vote followed Health Secretary Robert F. Kennedy Jr.'s push to make peptides more accessible and overrode FDA staff, who said evidence did not show the drugs improved any condition and flagged risks including liver injury and allergic reactions.
More than 1,000 U.S. patients have told doctors they used BPC-157 since 2020, according to an unpublished health-record analysis, while adverse-event reports and patient accounts describe migraines, numbness, pain, fatigue and prolonged emotional blunting.
Supporters say regulated compounding would be safer than today's research-chemical market, but critics argue it could mislead consumers into treating unapproved drugs as validated therapies and further reduce incentives to run clinical trials.
The FDA has not made a final decision, leaving a fast-growing peptide market caught between influencer-driven demand, sparse human data and mounting safety concerns.